CTRI/2020/02/023237招募中4 期
An open label, multi-centric, prospective clinical trial to evaluate safety and efficacy of fixed dose combination of Montelukast 10 mg plus Acebrophylline SR 200 mg tablet in patients having bronchial asthma in India
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female patient with age 18 - 65 years (both inclusive)
- •2.Patient having confirmed diagnosis of asthma as per GINA 2018 guideline since at least 3 months prior to screening
- •3.Patient having current sign/symptoms of asthma or need for SABA more than twice a week
- •4.Patient who is suitable to take Montelukast and Acebrophylline as per GINA 2018 guideline
- •5.Female patient of childbearing potential, willing to use effective contraception during the study and willing to undergo pregnancy test. Effective contraceptive include (e.g. barrier method with spermicide). The calendar method, withdrawal, or an IUD is NOT an acceptable method ?
- •6.Except asthma disorder patient is judged to be in general good health to participate in trial based on medical history and physical examination as assessed by the Investigator
- •7.Written informed consent signed by patient and willing to comply with the study procedure
排除标准
- •1.Pregnant or lactating female patient
- •2.Hospitalization due to exacerbation of asthma within the previous 12 weeks preceding study entry (screening visit)
- •3.Patient with clinically relevant upper respiratory tract infection 4 weeks prior or lower respiratory tract infection 8 weeks prior to the screening visit as judged by investigators
- •4.Patient has a history of oral or parenteral steroids 4 weeks prior & depot steroid 12 weeks prior to enrollment
- •5.Patient who had received leukotriene antagonist and/ or Acebrophylline within 3 days of enrolment
- •6.Patient with concurrent, previous or possible alcohol dependence, drug dependence or narcotic addiction as per DSM-5
- •7.Patient who have earlier participated in any other clinical trial within three months of screening
- •8.Patient with a known history of clinically significant (including but not limited to) acute myocardial infarction, impaired hemodynamics, psychiatric, hepatic or/and renal disorders, Ambroxol allergy, GI disorders, phenylketonuria, pneumonia, pulmonary fibrotic disease, active tuberculosis, chronic obstructive pulmonary disease (COPD) or pneumothorax convulsion, arrhythmia, CAD, cardiac insufficiency and hyperthyroidism
- •9.Patient with known history of Hypersensitivity to Acebrophylline or Montelukast or any other leukotriene antagonists or asprin or theophylline or any other xanthine derivative
- •10.History of hepatitis B, hepatitis C or HIV infection
- •11.Patient with type 2 diabetes (HbA1c > 9 % at screening)
- •12.Patient with current history of uncontrolled hypertension (SeSBP = 140 and/ or SeDBP = 90 mm of Hg)
- •13.Current smoker or past smoker with a smoking history of = 10 pack years
- •14.Patient with clinically significant disorder that, in the opinion of the investigator, would result in jeopardizing patient’s safety and efficacy of the drug
- •15.Patient judged unfit for this study by investigator
- •16.Investigator, study personnel, sponsor representatives and their first degree relatives
研究者
相似试验
已完成
2 期
Clinical study on JPF-16 Capsules in Sexual Dysfunction in FemalesCTRI/2017/06/008791Chatarubhuj Pharmaceutical Co30
已完成
2 期
Clinical study on Ayuvita Forte Capsule in irregular periods with cysts in ovary.CTRI/2019/11/022183Welex Laboratories Pvt Ltd25
已完成
不适用
A clinical trial to test the safety and effectiveness of Neuralzhein in management of memory loss related to age.CTRI/2019/08/020711exxus Laboratories DBA OPUS PHARMA
已完成
3 期
To evaluate safety and performance of CREDENCEâ?¢ BtK Sirolimus Eluting BioResorbable Peripheral Scaffold System in subjects with Critical Limb Ischemiafollowing Percutaneous Transluminal Angioplasty of below the knee arteries.CTRI/2016/11/007473Meril Life Sciences Pvt Ltd30
招募中
1 期
A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with TheraSphere followed by immunotherapy (durvalumab and tremelimumab treatment)Hepatocellular CarcinomaMedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104CTIS2023-508945-41-00Biocompatibles UK Limited107